CTNNB1 and hepatocellular carcinoma: We report strong in vitro and vivo efficacy of a novel LNP-formulated siRNA targeting CTNNB1 mRNA transcript for treatment of β-catenin-mutated HCC as monotherapy in early-stage disease or in combination with ICI in advanced-stage disease.